Xspray Pharma AB (XSPRAY) Price & Analysis

Compare

3 Followers

XSPRAY Stock Chart & Stats

kr31.20

kr0.60(1.95%)

At close: Mar 06 4:00 PM EST

kr31.20

kr0.60(1.95%)

Day’s Range― - ―

52-Week Rangekr22.59 - kr64.10

Previous CloseN/A

Volume2.99K

Average Volume (3M)297.70K

Market Cap

kr1.10B

Enterprise Valuekr1.12B

Total Cash (Recent Filing)kr153.75M

Total Debt (Recent Filing)kr170.11M

Price to Earnings (P/E)―

Beta1.09

Next Earnings

May 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.89

Shares Outstanding41,742,340

10 Day Avg. Volume602,659

30 Day Avg. Volume297,696

Financial Highlights & Ratios

PEG Ratio0.15

Price to Book (P/B)2.00

Price to Sales (P/S)0.00

P/FCF Ratio-6.26

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)12.03

Revenue Forecast (FY)kr157.50M

Bulls Say, Bears Say

Bulls Say

Proprietary HyNap PlatformXspray’s HyNap formulation platform is a durable technical asset that targets improved bioavailability and differentiated dosage forms. A repeatable platform lowers development risk versus new chemical entities, supports multiple reformulation programs, and enhances partnership appeal over the medium term.

Balance Sheet Equity BufferA substantial equity base provides a multi-quarter financial cushion, enabling continued R&D and partnership investment without immediate insolvency pressure. This equity buffer increases strategic optionality for licensing, collaborations, or staged commercialization over the next 2–6 months.

Licensing-driven Business ModelAn out‑licensing and royalty-focused model is capital-efficient and aligns incentives with partners who handle late‑stage development and commercialization. This structure can yield milestone and royalty revenue with lower ongoing capex, supporting sustainable growth if clinical/regulatory milestones are achieved.

Bears Say

No Commercial RevenueAbsence of commercial sales across multiple years means the firm has not yet validated market demand or payer acceptance for any HyNap product. Without revenues, the company remains dependent on financing and milestones, increasing execution and commercialization risk over the medium term.

Worsening Cash BurnOperating cash flow deterioration and deeply negative free cash flow materially shorten runway absent new funding or cost cuts. Persistent cash burn elevates the likelihood of dilutive equity raises or debt financing, which can constrain long‑term investment in programs and slow progress toward commercialization.

Rising LeverageRapid growth in debt increases fixed financial obligations and refinancing risk, especially given no operating revenue. Higher leverage reduces financial flexibility, raises interest costs, and can pressure strategic choices (licensing vs self‑commercialization) if cash flow does not improve in the coming months.

Xspray Pharma AB News

Xspray Pharma Wins FDA Review Slot for Dasynoc Ahead of Planned 2026 Dual Launch

Xspray Pharma AB ( ($SE:XSPRAY) ) just unveiled an update. Xspray Pharma has had its resubmitted New Drug...

1d ago

Xspray Pharma Resubmits FDA Application for Leukemia Drug Dasynoc

The latest update is out from Xspray Pharma AB ( ($SE:XSPRAY) ). Xspray Pharma has re-submitted its New...

14d ago

Xspray Pharma installs new CEO as it pivots to commercial growth

Xspray Pharma AB ( ($SE:XSPRAY) ) has shared an announcement. Xspray Pharma has appointed Blake Leitch as its...

15d ago

Xspray Pharma Narrows 2025 Loss as FDA Sets Review Date for XS003

The latest update is out from Xspray Pharma AB ( ($SE:XSPRAY) ). Xspray Pharma reported no net sales...

29d ago

Xspray Pharma Achieves Key Milestones in Q3 2025

Xspray Pharma AB ( ($SE:XSPRAY) ) has issued an update. Xspray Pharma’s Q3 2025 report highlights significant developments,...

4M ago

Xspray Pharma’s XS003 NDA Accepted by FDA with PDUFA Date Set

The latest announcement is out from Xspray Pharma AB ( ($SE:XSPRAY) ). Xspray Pharma AB announced that the...

5M ago

Xspray Pharma Announces Nomination Committee for 2026 AGM

Xspray Pharma AB ( ($SE:XSPRAY) ) has shared an announcement. Xspray Pharma AB has announced the composition of...

5M ago

Xspray Pharma Faces FDA Approval Delay for Dasynoc Due to Manufacturing Issues

Xspray Pharma AB ( ($SE:XSPRAY) ) has issued an announcement. Xspray Pharma AB has received a Complete Response...

5M ago

Xspray Pharma Expands Share Base Amid High Investor Interest

Xspray Pharma AB ( ($SE:XSPRAY) ) has provided an update. Xspray Pharma AB has increased its number of...

5M ago

Xspray Pharma’s Rights Issue Oversubscribed, Secures SEK 161 Million

Xspray Pharma AB ( ($SE:XSPRAY) ) has provided an update. Xspray Pharma AB announced that its rights issue...

6M ago

XSPRAY FAQ

What was Xspray Pharma AB’s price range in the past 12 months?

Xspray Pharma AB lowest stock price was kr22.59 and its highest was kr64.10 in the past 12 months.

What is Xspray Pharma AB’s market cap?

Xspray Pharma AB’s market cap is kr1.10B.

When is Xspray Pharma AB’s upcoming earnings report date?

Xspray Pharma AB’s upcoming earnings report date is May 06, 2026 which is in 55 days.

How were Xspray Pharma AB’s earnings last quarter?

Xspray Pharma AB released its earnings results on Feb 12, 2026. The company reported -kr0.886 earnings per share for the quarter, missing the consensus estimate of kr1.754 by -kr2.64.

Is Xspray Pharma AB overvalued?

According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Xspray Pharma AB pay dividends?

Xspray Pharma AB does not currently pay dividends.

What is Xspray Pharma AB’s EPS estimate?

Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Xspray Pharma AB have?

Xspray Pharma AB has 41,742,340 shares outstanding.

What happened to Xspray Pharma AB’s price movement after its last earnings report?

Xspray Pharma AB reported an EPS of -kr0.886 in its last earnings report, missing expectations of kr1.754. Following the earnings report the stock price went up 4.348%.

Which hedge fund is a major shareholder of Xspray Pharma AB?

Currently, no hedge funds are holding shares in SE:XSPRAY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Xspray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.